Welcome, Introduction, and Baseline Assessment
Perplexities in non-metastatic RCC at initial diagnosis
Immuno-oncology combinations in first-line metastatic RCC
Case Examples: Planning optimal first-line treatment for individual patients with advanced or metastatic RCC
Selecting therapy for patients with progressive RCC after 1 or more previous lines of treatment
Case Examples: Optimal treatment for patients with progressive RCC after 1 or more previous lines of therapy
Management of adverse events associated with immunotherapy-based combinations for advanced RCC
Looking Ahead: Ongoing clinical trials in RCC
Date / Time
Brian Costello, MD
Associate Professor of Oncology and Urology
Division of Medical Oncology
Eric Jonasch, MD
Professor, Genitourinary Medical Oncology
The University of Texas MD Anderson Cancer Center
Elizabeth R. Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with RCC.
This educational program is intended for oncologists, urologists, physician assistants, nurses, pharmacists, and other healthcare professionals involved in the care of patients with RCC.
Upon completion of this activity, participants should be able to:
- Review clinical data on systemic treatment approaches for patients with operable, advanced or metastatic RCC
- Identify patients most likely to benefit from targeted and/or immune checkpoint inhibitor–based combination therapies based on risk and biomarker assessment, along with patient medical and treatment history
- Plan optimal first-line treatment for individual patients with advanced or metastatic RCC, taking into consideration targeted and immune checkpoint inhibitor combination options, available clinical evidence, expert recommendations, and patient preferences
- Apply guideline-directed therapeutic strategies to optimize the sequence of therapies in order to provide the best outcome to patients with RCC
- Manage specific disease-related complications or adverse events associated with currently approved monotherapies and therapy combinations for advanced RCC
- Select patients who may benefit from ongoing clinical trials based on tumor characteristics, previous treatment, and patient characteristics and preferences
Joint Accreditation Statement
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
NCCN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
NCCN designates this educational activity for a maximum of 1.5 contact hours.
Continuing Pharmacy Education
NCCN designates this application-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit.
3/1 UAN: JA4008196-0000-22-024-L01-P
3/11 UAN: JA4008196-0000-22-023-L01-P
You must complete the post-test and evaluation within 30 days of the activity. Continuing pharmacy education credit is reported to the CPE Monitor once the post-test and evaluation are completed. Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth or your credit cannot be reported. If you have not already done so, please complete your e-profile at https://nabp.pharmacy/ to obtain your NABP e-Profile ID.
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content will be reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, will be fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.